DeepMed Research

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)

Phase 1

Terminated

Conditions: Acute Myelogenous Leukemia
Chronic Myelomonocytic Leukemia

Interventions: Drug: DTGM

First Posted Date: 2003-12-23

Last Posted Date: 2012-02-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 7

Registration Number: NCT00074750

Locations: 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

Comparing Fresh Random Platelets and Autologous Cryopreserved Thrombosol Treated Autologous Platelets

Phase 3

Terminated

Conditions: Lymphoma
Leukemia

Interventions: Biological: Platelet Transfusion

First Posted Date: 2003-12-23

Last Posted Date: 2012-08-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 4

Registration Number: NCT00074763

Locations: 🇺🇸
UT M.D. Anderson Cancer Center, Houston, Texas, United States

Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Biological: Filgrastim (G-CSF)
Drug: Carmustine
Drug: Cisplatin
Drug: Cyclophosphamide (CTX)
Drug: Etoposide
Drug: Thiotepa
Procedure: Peripheral Blood Stem Cell Transplantation

First Posted Date: 2003-11-24

Last Posted Date: 2018-11-06

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 184

Registration Number: NCT00002836

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Campath-1H
Drug: Rituximab

First Posted Date: 2003-10-22

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 48

Registration Number: NCT00071396

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Alopecia Areata Registry

Active, not recruiting

Conditions: Alopecia Areata
Alopecia Universalis
Autoimmune Hair Loss
Alopecia Partialis
Alopecia Totalis

First Posted Date: 2003-09-30

Last Posted Date: 2019-05-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3100

Registration Number: NCT00069589

Locations: 🇺🇸
Columbia University, New York, New York, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
University of Colorado - UCHSC - Health Science Center at Fitzsimons, Aurora, Colorado, United States

and more 2 locations

Irinotecan in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2003-09-24

Last Posted Date: 2018-11-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 50

Registration Number: NCT00003245

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: Celecoxib
Drug: Gemcitabine Hydrochloride

First Posted Date: 2003-09-11

Last Posted Date: 2018-10-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 28

Registration Number: NCT00068432

Locations: 🇺🇸
CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸
CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States
🇺🇸
M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States

and more 8 locations

Chemotherapy, Interferon Alfa, and Radiation Therapy in Treating Patients Who Have Undergone Surgery For Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Biological: Recombinant Interferon Alfa
Drug: Cisplatin
Drug: Fluorouracil
Radiation: Radiation Therapy

First Posted Date: 2003-09-11

Last Posted Date: 2012-02-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 29

Registration Number: NCT00068575

Locations: 🇺🇸
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States

Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS)

Phase 2

Completed

Conditions: Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia

Interventions: Drug: Decitabine

First Posted Date: 2003-08-28

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 128

Registration Number: NCT00067808

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Pegfilgrastim (Neulasta)
Procedure: Apheresis

First Posted Date: 2003-08-26

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 50

Registration Number: NCT00067639

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy